The introduction of the 750mcg teriparatide formulation in Australia has seen restricted distribution to date. Primarily reserved for patients with severe bone loss who have not responded to other treatments , access is strictly managed. Existing supply levels are tight , and sufferers should verify from their physician the current information on o